SOLV vs BAX — Key Metrics
| Metric | SOLV (SOLVENTUM CORP) | BAX (BAXTER INTERNATIONAL INC) |
|---|---|---|
| Price | 86.48 | 26.16 |
| Market Cap | 14.68 Billion | 13.53 Billion |
| P/E (TTM) | 97.17 | -18.42 |
| P/B (Quarterly) | 3.08 | 1.87 |
| P/S (TTM) | 1.8 | 1.17 |
| Net Profit Margin (TTM) | 1.9 | -6.2 |
| Gross Margin (TTM) | 54.8 | 30.1 |
| ROE (TTM) | 3.2 | -11.6 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Outperform
Recommendation Summary
Stock SOLV is projected to outperform the market, stock BAX is projected to greatly outperform the market. Upfront Recommendation: BAX.
Financial Metrics
| SOLV | Metrics | BAX |
|---|---|---|
| $86.48 | Price | $26.16 |
| — | Market Capitalization | — |
| 1.8 | Price to Sales | 1.17 |
| 47.65 | Price to FCF Ratio | 11.93 |
| 3.28 | Price to Gross Profit | 3.87 |
| 20.3 | Price to R&D | 26.08 |
| 3.98 | Price to Current Assets | 1.98 |
SOLV vs BAX at a glance
Solventum Corp (SOLV) and Baxter International INC (BAX) are both in the Healthcare sector. They are similar in size: $14.7 billion and $13.5 billion in market value.
On trailing-twelve-month figures, SOLV trades at 1.8 times trailing sales and BAX at 1.2; net profit margins are 1.9% and -6.2%.
The Upfront Investment model currently rates SOLV Outperform and BAX Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.